AbbVie (ABBV) Treasury Shares (2013 - 2026)
AbbVie (ABBV) posted quarterly Treasury Shares of $10.6 billion for Q1 2026, up 1001.87% year-over-year from $963.0 million in Q1 2025, and up 16.02% quarter-over-quarter from $9.1 billion in Q4 2025.
AbbVie (ABBV) Treasury Shares (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Treasury Shares for 14 consecutive years, with $10.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 1001.87% year-over-year to $10.6 billion; the TTM figure through Mar 2026 stood at $10.6 billion (up 1001.87% YoY), while the FY2025 annual figure was $9.1 billion, up 11.52% from the prior year.
- Treasury Shares grew to $10.6 billion in Q1 2026 per ABBV's latest filing, from $9.1 billion in the prior quarter.
- Across five years, Treasury Shares topped out at $77.1 million in Q1 2026 and bottomed at $44.6 million in Q1 2022.
- Historically, Treasury Shares has averaged $60.4 million across 5 years, with a median of $64.2 million in 2024.
- Annual changes were most pronounced in 2022 — Treasury Shares tumbled 98.87% — and 2024, when it jumped 33650.0%.
- AbbVie's Treasury Shares stood at $4.6 billion in 2022, then soared by 42.21% to $6.5 billion in 2023, then climbed by 25.53% to $8.2 billion in 2024, then gained by 11.52% to $9.1 billion in 2025, then climbed by 16.02% to $10.6 billion in 2026.
- Business Quant data shows ABBV's Treasury Shares at $10.6 billion in Q1 2026, $9.1 billion in Q4 2025, and $9.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.62 Bn |
| Jun 30, 2026 | 77.11 Mn |
| Jun 30, 2026 | 77.11 Mn |
| Jun 30, 2026 | 10.62 Bn |
| Mar 31, 2026 | 77.08 Mn |
| Mar 31, 2026 | 77.08 Mn |
| Mar 31, 2026 | 10.61 Bn |
| Mar 31, 2026 | 10.61 Bn |
| Dec 31, 2025 | 70.80 Mn |
| Dec 31, 2025 | 9.15 Bn |
| Dec 31, 2025 | 9.15 Bn |
| Dec 31, 2025 | 70.80 Mn |
| Sep 30, 2025 | 9.14 Bn |
| Sep 30, 2025 | 70.79 Mn |
| Sep 30, 2025 | 70.79 Mn |
| Sep 30, 2025 | 9.14 Bn |
| Jun 30, 2025 | 70.83 Mn |
| Jun 30, 2025 | 9.15 Bn |
| Jun 30, 2025 | 9.15 Bn |
| Jun 30, 2025 | 70.83 Mn |